Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Medical University Innsbruck Pfizer |
---|---|
Information provided by: | Medical University Innsbruck |
ClinicalTrials.gov Identifier: | NCT00535379 |
Clinical Part:
The objective of this study is to determine the efficacy and safety of SUTENT in patients with recurrent or progressive glioblastoma multiforme.Patients with tissue based diagnosis of intracranial glioblastoma multiforme, above 18 years of age and of both genders, who have a first tumor recurrence or progress after surgery, radiation- and chemotherapy will be included. The hypothesis is that SUTENT will significantly increase the progression free survival rate at 6 months in the study population.
Condition | Intervention | Phase |
---|---|---|
Glioblastoma Multiforme |
Drug: Sunitinib |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-Arm Phase II Clinical Trial Including Ranslational Research Studies |
Estimated Enrollment: | 70 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | June 2010 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Sunitinib
Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Bone Marrow Reserve - Platelets ≥ 75.000/μL
Exclusion Criteria:
Exclusion of patients in the event of
Significant Co-Morbidities within 12 months prior to study enrollment
Significant Co-Morbidities at Baseline Evaluation
Pregnancy, Breastfeeding and Non-Contraception
Evidence of increased intracranial pressure
Contact: Guenther Stockhammer, MD, Prof. | +43/512/504 ext 81171 | guenther.stockhammer@i-med.ac.at |
Contact: Markus Hutterer, MD | +43/512/504 ext 82271 | markus.hutterer@i-med.ac.at |
Austria | |
Medical University Vienna | Recruiting |
Vienna, Austria | |
Contact: Christine Marosi, MD, Prof. +43/1/40400 ext 4429 crhsitine.marosi@meduniwien.ac.at | |
Principal Investigator: Christine Marosi, MD, Prof. | |
LNK Wagner-Jauregg | Recruiting |
Linz, Austria | |
Contact: Johanna Buchroithner, MD +43/554/62 ext 25921 johanna.buchroithner@gespag.at | |
Principal Investigator: Johanna Buchroithner, MD | |
LKH Feldkirch | Recruiting |
Feldkirch, Austria | |
Contact: Karl Rössler, MD +43/5522/303 ext 9191 karl.roessler@lkhf.at | |
Principal Investigator: Karl Rössler, MD | |
Kaiser-Franz-Josef Spital Wien | Recruiting |
Wien, Austria | |
Contact: Wolfgang Grisold, MD, Prof. +43/1/60191 ext 2008 wolfgang.grisold@wienkav.at | |
Principal Investigator: Wolfgang Grisold, MD, Prof. | |
Medical University Innsbruck | Recruiting |
Innsbruck, Austria, 6020 | |
Contact: Guenther Stockhammer, MD, Prof. +43/512/504 ext 81171 guenther.stockhammer@i-med.ac.at | |
Contact: Markus Hutterer, MD +43/512/504 ext 82271 markus.hutterer@i-med.ac.at | |
Principal Investigator: Guenther Stockhammer, MD, Prof. | |
Sub-Investigator: Markus Hutterer, MD | |
Sub-Investigator: Herwig Kostron, MD, Prof. | |
Sub-Investigator: Armin Muigg, MD, Prof. |
Principal Investigator: | Guenther Stockhammer, MD, Prof. | Medical University Innsbruck |
Responsible Party: | Department of Neurology ( Medical University Innsbruck ) |
Study ID Numbers: | EUDRACT-Nr. 2007-002142-37 |
Study First Received: | September 25, 2007 |
Last Updated: | February 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00535379 History of Changes |
Health Authority: | Austria: Agency for Health and Food Safety; Austria: Ethikkommission; Germany: Ethics Commission; Germany: Federal Institute for Drugs and Medical Devices |
glioblastoma multiforme sunitinib recurrent progressive |
Neuroectodermal Tumors Glioblastoma Astrocytoma Sunitinib Neoplasms, Germ Cell and Embryonal Neuroepithelioma |
Glioblastoma Multiforme Glioma Angiogenesis Inhibitors Recurrence Neoplasms, Glandular and Epithelial |
Glioblastoma Neoplasms by Histologic Type Astrocytoma Antineoplastic Agents Growth Substances Physiological Effects of Drugs Neoplasms, Nerve Tissue Angiogenesis Inhibitors Pharmacologic Actions Neuroectodermal Tumors |
Neoplasms Sunitinib Neoplasms, Germ Cell and Embryonal Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Glioma Neoplasms, Neuroepithelial Neoplasms, Glandular and Epithelial |